default home page content here
Merck Loses Australian Vioxx Lawsuit
newsinferno.com
We just wrote that Merck & Co. made a final $4.1 billion payment to its Vioxx settlement fund. According to a recent Associated Press (AP) report, final payouts to former Vioxx users or their survivors should be made by the end of June. Now, Bloomberg News is reporting that Merck & Co.s Australian unit neglected to [...]
posted on March 06, 2010 in
Big Pharma
AstraZeneca cutting 550 R&D jobs over next two years
ledgerdelaware.com
AstraZeneca announced it will cut back research in Delaware. An estimated 550 jobs will be eliminated over the next two years in Delaware. AstraZeneca is closing research sites in Europe and will add some jobs in Boston. The cuts amount to about one third of the company’s R&D jobs in Delaware.
posted on March 05, 2010 in
Big Pharma
Merck seeks to stop copy of Vytorin
nj.com
2008 STAR-LEDGER FILE PHOTOVytorin, a cholesterol drug manufactured by Merck that combines Zocor and Zetia. WHITEHOUSE STATION—Merck & Co. and its Schering unit sued Teva Pharmaceutical Industries Ltd. to prevent it from selling a generic version of the…
posted on March 05, 2010 in
Big Pharma
Merck seeks to stop copy of Vytorin
nj.com
Merck & Co. and its Schering unit sued Teva Pharmaceutical Industries Ltd. to prevent it from selling a generic version of the…
posted on March 05, 2010 in
Big Pharma
Moody’s Investors Service upgrades Mylan’s credit ratings
news-medical.net
Mylan Inc. today reported that Moody’s Investors Service upgraded the company’s credit ratings, including the “Corporate Family Rating” to Ba3 from B1 and the senior secured bank rating to Ba2 from Ba3. Moody’s also affirmed Mylan’s SGL-1 Speculative Grade Liquidity Rating.
posted on March 05, 2010 in
Big Pharma
Group to discuss drugs job loss
news.bbc.co.uk
A group set up to respond to the loss of 1,200 jobs at AstraZeneca in Leicestershire is to meet for the first time later.
posted on March 05, 2010 in
Big Pharma
choose a category to see older entries